Skip to main content
Equibles

Joel Ackerman

CFO

Davita Inc. (DVA)

Board Member

Champions Oncology, Inc. (CSBR)

Equibles does not estimate personal net worth.

Get an email with a short summary when Davita Inc. publishes a filing, an earnings call transcript or a press release.

Get DVA alerts

About Joel Ackerman

Joel Ackerman is recorded as CFO at Davita Inc. (DVA) and Board Member at Champions Oncology, Inc. (CSBR). The newest filing on record that lists Joel Ackerman as Board Member at Champions Oncology, Inc. (CSBR) is dated August 28, 2026. The proxy statement of Davita Inc. reports total compensation of $6,129,962 for Joel Ackerman in fiscal 2025, including a base salary of $834,616. Disclosed compensation is on record for 8 fiscal years. Joel Ackerman has spoken on 25 earnings calls across 1 company, most recently for Davita Inc. on August 4, 2026. Davita Inc. is classified in the Medical Care Facilities industry within the Healthcare sector. Champions Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Davita Inc. includes Kent J. Thiry (Chairman), Pamela M. Arway (Chairman and Board Member), David P. Maughan (COO) and 7 others.

Joel Ackerman on recent calls

“I'll begin with the details on our second quarter results and close with some additional color on the remainder of the year. Second quarter adjusted operating income was $579 million, adjusted earning per share was $4.02, and free cash flow was $256 million.”
CFO, Davita Inc. Q2 FY2026 Earnings Call ·
“Today, I'll provide details on our first quarter results, then give you some more context on the update to 2026 guidance that Javier shared. First quarter adjusted operating income was $482 million.”
CFO, Davita Inc. Q1 FY2026 Earnings Call ·
“First, I'll provide some detail on our fourth quarter and full year 2025 results, and then share a detailed breakdown of our 2026 guidance. Fourth quarter adjusted operating income was $586 million, bringing full year adjusted operating income to $2,094 million. dollars.”
CFO, Davita Inc. Q4 FY2025 Earnings Call ·
“Third quarter adjusted operating income was $517 million, adjusted earnings per share was $2.51, and free cash flow was $604 million. I'll provide detail on the individual components of our results, beginning with U.S. dialysis.”
CFO, Davita Inc. Q3 FY2025 Earnings Call ·
“Second quarter adjusted operating income was $551 million. Adjusted earnings per share was $2.95, and free cash flow was $157 million. I'll provide detail on the individual components of our results, beginning with U.S. dialysis.”
CFO, Davita Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Davita Inc.

Leadership on record at Champions Oncology, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Davita Inc. (DVA) $834,616 $6,129,962
2024 Davita Inc. (DVA) $769,231 $6,349,613
2023 Davita Inc. (DVA) $700,000 $6,868,181
2022 Davita Inc. (DVA) $700,000 $4,702,708
2021 Davita Inc. (DVA) $700,000 $4,740,820
2020 Davita Inc. (DVA) $726,923 $5,238,776
2019 Davita Inc. (DVA) $700,000 $6,538,164
2018 Davita Inc. (DVA) $700,000 $6,620,282

Recent activity

Show 13 earlier activities